Vernal Keratoconjunctivitis Market Analysis & Forecast: 2026-2033
The Vernal Keratoconjunctivitis Market size is anticipated to grow at a CAGR of 3.6% with USD 414.0 Mn in 2026 and is expected to reach USD 530.3 Mn by 2033. The market growth is primarily driven by the increasing prevalence of allergic eye diseases, rising incidence of seasonal allergies among children and young adults, and growing awareness regarding early diagnosis and treatment of ocular disorders. According to the American Academy of Ophthalmology (AAO), Vernal Keratoconjunctivitis (VKC) predominantly affects children and adolescents aged 5–20 years, with peak incidence occurring between 11 and 13 years of age, and males are affected approximately twice as often as females.
Rising air pollution levels, warming climate, and extended pollen seasons are leading to more cases of allergic eye diseases, thus fueling the need for proper VKC treatments. Urbanization and environmental changes are increasing exposure to allergens, especially young ones living in tropical and subtropical climates, to be exposed to more allergens and irritants.
According to the World Health Organization (WHO) estimates that 99% of the world's population breathes air that is above WHO air quality guidelines limits, thus exposing themselves to air pollutants that could worsen their allergic or inflammatory eye diseases.
Improved availability of ophthalmological care facilities and access to healthcare is contributing to the detection and treatment of vernal keratoconjunctivitis. Various government campaigns focused on avoiding unnecessary blindness and spreading awareness about eye disorders are promoting early diagnosis and stimulating market growth.
According to the Royal College of Ophthalmologists and College of Optometrists (2025), the UK Eye Care Data Hub, which has been recently established, is expected to record an increase in cases of various eye diseases by the end of the coming decade, such as 24.4% of the late age-related macular degeneration, 15.9% of the primary open-angle glaucoma, and 16.7% of the vision-threatening cataracts.
|
Current Event |
Description and its Impact |
|
Santen Launchs Verkazia® in China, Expanding Access to Severe VKC Treatment |
|
|
Harrow Reintroduces Verkazia® in the U.S. to Improve Availability of FDA-Approved Therapy |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
On the basis of drug type, the Verkazia segment is projected to account for the largest Vernal Keratoconjunctivitis market share of 31.8% in 2026. The segment’s growth is owing to the increasing adoption of cyclosporine ophthalmic emulsions for severe VKC and favorable clinical outcomes in pediatric patients.
According to the European Medicines Agency (EMA), in the pivotal VEKTIS study involving 169 children and adolescents with severe VKC, approximately 55% of patients treated with Verkazia achieved at least a 50% improvement in corneal damage after four months, compared with around 28% in the control group. This clinical efficacy has accelerated physician confidence and expanded the use of Verkazia as a steroid-sparing therapy.
In July 2023, Harrow acquired Santen's branded ophthalmic portfolio in North America, including Verkazia®, strengthening its ophthalmology business and commercial infrastructure for VKC treatment.
To learn more about this report, Request Free Sample
On the basis of treatment, the cyclosporine market is expected to gain 29.4% of the market by 2026. This is attributed to the ability of cyclosporine to avoid use of steroids and preference for long-term treatment of moderate-to-severe disease.
In December 2025, Amneal Pharmaceuticals obtained FDA approval of Cyclosporine Ophthalmic Emulsion 0.05%, adding to its repertoire of ophthalmic drugs and its sterile manufacturing capacity. While the drug is used for treating dry eye disease, the approval makes the market more favorable for cyclosporine eye preparations.
On the basis of dosage form, the gel segment is projected to account for the largest share of 42.6% in 2026. The segment’s growth is owing to improved ocular residence time, sustained drug release, and enhanced patient compliance.
As reported by a 2025 review on Pharmaceutics, the ocular bioavailability of conventional eye drops is less than 5% because of tear flow and nasolacrimal drainage. In order to counter these limitations, researchers are working on gels and in-situ gels for the eye to ensure good contact with the cornea and efficient drug delivery.
In January 2025, the World Health Organization (WHO) reaffirmed its SPECS 2030 initiative to strengthen integrated people-centered eye care services worldwide, supporting broader access to specialist treatment and prescription medicines.
On the basis of distribution channel, the hospital pharmacy segment is projected to account for the largest Vernal Keratoconjunctivitis market share of 48.3% in 2026. The segment’s growth is owing to the prescription-based nature of immunomodulators and corticosteroids, increasing referrals to ophthalmology specialists, and the need for close monitoring of moderate-to-severe disease cases.
According to the International Council of Ophthalmology (ICO), there have been 232,866 ophthalmologists around the world as of 2025. With the increased number of ophthalmologists and specialized eye clinics, hospital-based diagnosing and managing of VKC cases have become more common, which is why prescriptions have been increasingly dispensed from hospital pharmacies.
In April 2025, Aditya Jyot Eye Hospital, now part of Dr. Agarwal's Eye Hospital network, inaugurated its renovated facility in Mumbai. The event emphasized expanding advanced eye care and outreach programs.
To learn more about this report, Request Free Sample
The Asia Pacific region is estimated to contribute to 41.7% of the world market share of Vernal Keratoconjunctivitis in 2026. This region has been witnessing high growth due to the presence of high prevalence of VKC cases in tropical and subtropical countries, increasing number of children, awareness of eye diseases and developments in eye treatment methods. There is also an increase in the incidence of steroid-sparing drugs in countries such as India, Japan and China.
According to WHO reported that less than half of the people in the Western Pacific region have access to eye-care services that are of good quality and can be afforded, hence the need for more ophthalmic care.
In December 2025, Santen Pharmaceutical Co., Ltd. announced the launch of Verkazia (Ciclosporin Eye Drops III) in China for the treatment of severe vernal keratoconjunctivitis (VKC) in children and young adults aged four years and above.
North America is expected to witness the fastest growth over the forecast period. The region's growth is owing to increasing adoption of advanced ophthalmic therapies, strong healthcare infrastructure, rising awareness of allergic eye disorders, and expanding access to specialist eye care services. Growing investments in ophthalmology research and favorable reimbursement frameworks are further supporting market expansion.
According to the National Eye Institute (NEI), approximately 93 million adults in the United States are at high risk for serious vision loss, yet only half visit an eye doctor annually, highlighting the growing need for early diagnosis and specialist intervention.
In June 2026, Harrow introduced VERKAZIA (cyclosporine ophthalmic emulsion 0.1%) in the United States to improve availability of the only FDA-approved treatment for VKC, strengthening treatment access and supporting market growth.
The U.S. Vernal Keratoconjunctivitis Market is growing steadily due to rising awareness about allergic pediatric eye disease conditions, ophthalmological structure, and availability of sophisticated steroid-sparing treatment options. The country has a strong specialist network, and immunomodulatory treatment options are being increasingly used for treating serious ocular surface conditions.
Additionally, the CDC reported in 2025 that nearly 6.8% of U.S. children suffer from respiratory allergies, often associated with allergic ocular manifestations, supporting demand for allergy-related eye treatments.
China's Vernal Keratoconjunctivitis Market is growing due to higher spending on healthcare, increase in number of children, and development of ophthalmology infrastructure. Growing awareness about allergic eye disorders and presence of new treatment options are driving the market growth.
According to the World Health Organization (WHO), China began implementing the WHO SPECS 2030 Initiative and China National Action Plan for Refractive Error in October 2025, which was a crucial move towards achieving universal coverage in terms of vision care.
Some of the major key players in Vernal Keratoconjunctivitis Market are Santen, Novartis Pharmaceuticals, Senju Pharmaceutical, Allakos, iCo Therapeutics, and Akari Therapeutics.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 414.0 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.6% | 2033 Value Projection: | USD 530.3 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Santen, Novartis Pharmaceuticals, Senju Pharmaceutical, Allakos, iCo Therapeutics, and Akari Therapeutics |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
